MBX Biosciences (NASDAQ:MBX) Shares Gap Up - Should You Buy?

Key Points

• MBX Biosciences shares experienced a significant jump, opening at $22.40 after a previous close of $10.00, with the stock last trading at $24.12 and a volume of over 17 million shares.
• Wall Street Zen upgraded MBX Biosciences from a "sell" rating to a "hold" rating, indicating a positive outlook for the company.
• The company has a market capitalization of $621.75 million and is engaged in developing novel precision peptide therapies for endocrine and metabolic disorders.

MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report)'s share price gapped up prior to trading on Monday . The stock had previously closed at $10.00, but opened at $22.40. MBX Biosciences shares last traded at $24.12, with a volume of 17,430,284 shares changing hands.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of MBX Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, September 13th.

MBX Biosciences Trading Down 1.0%

The stock has a market capitalization of $665.42 million and a price-to-earnings ratio of -4.36.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.